OCULAR THERAPEUTIX INC

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

OCUL$6.61-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)


· · Year Ended December 31, ·

· 2024 · 2023 · 2022
Cash flows from operating activities: · · ·
Net loss	$(193,506)	$(80,736)	$(71,038)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	33,109	17,825	16,964
Non-cash interest expense	3,734	6,106	4,853
Change in fair value of derivative liabilities	480	5,188	(13,841)
Depreciation and amortization expense	3,786	2,983	2,109
Gains and losses on extinguishment of debt, net	27,950	(14,190)	—
Gain on disposal of property and equipment	—	1	1
Changes in operating assets and liabilities:
Accounts receivable	(6,209)	(4,854)	(190)
Prepaid expenses and other current assets	(5,663)	(3,766)	723
Inventory	(735)	(331)	(724)
Accounts payable	(318)	583	(621)
Operating lease assets	505	1,570	(3,175)
Accrued expenses	3,638	773	1,644
Deferred revenue	(262)	427	963
Operating lease liabilities	(1,186)	(1,813)	2,729
Net cash used in operating activities	(134,677)	(70,234)	(59,603)
Cash flows from investing activities:
Purchases of property and equipment	(1,288)	(6,087)	(3,715)
Net cash used in investing activities	(1,288)	(6,087)	(3,715)
Cash flows from financing activities:
Proceeds from issuance of short-term bridge loan	—	2,000	—
Proceeds from issuance of Barings notes payable	—	82,474	—
Proceeds from exercise of stock options	14,741	551	514
Proceeds from issuance of common stock pursuant to employee stock purchase plan	1,016	851	940
Payments of debt refinancing costs	—	(5,184)	—
Proceeds from issuance of common stock upon public offering, net of issuance costs	—	117,261	—
Repayment of MidCap notes payable	—	(26,125)	—
Repayment from issuance of short-term bridge loan	—	(2,000)	—
Proceeds from issuance of common stock and pre-funded warrants upon private placement, net of issuance costs	316,353	—	—
Net cash provided by financing activities	332,110	169,828	1,454
Net increase in cash, cash equivalents and restricted cash	196,145	93,507	(61,864)
Cash, cash equivalents and restricted cash at beginning of period	197,571	104,064	165,928
Cash, cash equivalents and restricted cash at end of period	$393,716	$197,571	$104,064
Supplemental disclosure of cash flow information:
Cash paid for interest	$21,533	$5,464	$2,147
Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses	$121	$16	$1,384

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.